Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California. Show more

Location: 520 Newport Center Drive, Newport Beach, CA, 92660, United States | Website: https://www.evolus.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare

Market Cap

589.3M

52 Wk Range

$8.67 - $17.82

Previous Close

$9.14

Open

$9.13

Volume

796,102

Day Range

$9.07 - $9.38

Enterprise Value

651.6M

Cash

67.89M

Avg Qtr Burn

-5.754M

Insider Ownership

5.46%

Institutional Own.

85.33%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Evolysse™ Details Nasolabial fold lines	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Jeuveau (prabotulinumtoxinA-xvfs) Details Glabellar lines , Benign tumor	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Jeuveau “Extra-Strength” Details Glabellar lines	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.